Federal health officials are reporting substantial progress against opioid deaths, with new analyses documenting reduced prescription exposure and falling fatalities involving synthetic opioids. Misty Severi’s October 27 Just the News article highlighted an HHS announcement describing opioid mortality as its lowest since the 2017 public health emergency declaration.
The accompanying ASPE report examined a broader measure, the nation’s overall age adjusted death rate. CDC provisionally recorded 689.2 deaths per 100,000 people in 2025. That figure covers all causes of death, not opioids alone.
Drug overdoses explained nearly three quarters of the injury reduction, overwhelmingly involving synthetic opioids other than methadone, including fentanyl. Deaths in that specific overdose category fell from 45,917 in 2024 to 36,406 in 2025.
A separate pharmacy analysis summarized by HHS tracked March 2015 through March 2026. After population adjustment, opioid prescription dispensing fell to 45.3 percent of its starting level, while the number of patients receiving those prescriptions declined to 49.6 percent. Patients filling prescriptions for buprenorphine or naltrexone increased to 218 percent of the baseline.
Health Secretary Robert F. Kennedy Jr. credited the administration’s approach. “Those actions are saving lives and driving opioid deaths to the lowest in nearly a decade. We will keep pressing forward until every American struggling with addiction has a real path to recovery and a chance to rebuild a healthy life.”
Kathryn Burgum, an HHS senior adviser, emphasized continued support. “Through the President’s Great American Recovery, we will keep our focus on the people behind the numbers and the families counting on the Trump Administration to save more American lives.
These gains should strengthen demands for corporate accountability. Washington should also secure the border against drug trafficking while sustaining treatment and recovery. Permissiveness is not an option here.
